Contemporary use of Selexipag in pulmonary arterial hypertension associated with congenital heart disease: a case series

BACKGROUND: There are significant risks of parenteral prostacyclin use in patients with pulmonary arterial hypertension associated with congenital heart disease (PAH-CHD), which may limit their use. Selexipag is an oral, selective prostacyclin analogue that has been shown to reduce disease progressi...

Descripción completa

Detalles Bibliográficos
Autores principales: Blissett, Sarah, Blusztein, David, Mahadevan, Vaikom S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Case Series
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793171/
https://www.ncbi.nlm.nih.gov/pubmed/33442633
http://dx.doi.org/10.1093/ehjcr/ytaa320

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7793171/
https://www.ncbi.nlm.nih.gov/pubmed/33442633
http://dx.doi.org/10.1093/ehjcr/ytaa320

Ejemplares similares